Amgen Inc. (NASDAQ: AMGN) is a leading biotechnology company known for its innovative therapies and treatments. On March 5, 2026, David Risinger from Leerink Partners set a price target of $355 for Amgen. At that time, the stock was trading at $367.60, which is about 3.43% higher than the target. This suggests that the market might have a more optimistic view of Amgen's future performance.
Amgen is scheduled to present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026. The presentation will feature key executives, including Peter Griffith, the Executive Vice President and CFO, and Jasper van Grunsven, the Senior Vice President of Rare Disease. This event will be webcast live, allowing investors and the public to gain insights into Amgen's strategies and future plans.
Currently, Amgen's stock price is $367.60, reflecting a decrease of 3.08% or $11.67. Yesterday, the stock has fluctuated between $361.40 and $377.09. Over the past year, it has seen a high of $391.29 and a low of $261.43. This volatility indicates that the stock is subject to market fluctuations, which investors should consider.
Amgen's market capitalization is approximately $198.16 billion, making it a significant player in the biotechnology sector. The trading volume on the NASDAQ exchange is 2,592,566 shares, showing active investor interest. This level of activity suggests that Amgen remains a focal point for investors looking for opportunities in the biotech industry.
